Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cromolyn
Drug ID BADD_D00538
Description A chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells. It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack.
Indications and Usage For the management of patients with bronchial asthma. Also used in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.
Marketing Status approved
ATC Code S01GX01; R03BC01; D11AH03; R01AC01; A07EB01
DrugBank ID DB01003
KEGG ID D07753; D00526
MeSH ID D004205
PubChem ID 2882
TTD Drug ID D0G7IY
NDC Product Code Not Available
UNII Y0TK0FS77W
Synonyms Cromolyn Sodium | Sodium Cromoglycate | Cromoglycate, Sodium | Disodium Cromoglycate | Cromoglycate, Disodium | Aarane | Bicromat Spray | Cromoglycate | Opticrom | FPL-670 | FPL 670 | FPL670 | Intal | Lomudal | Nalcrom | Nasalcrom | Vicrom | Cromolyn | Cromoglicic Acid | Acid, Cromoglicic | Cromoglycic Acid | Acid, Cromoglycic
Chemical Information
Molecular Formula C23H16O11
CAS Registry Number 16110-51-3
SMILES C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pollakiuria20.02.02.007--
Polycythaemia01.07.01.001---
Presyncope02.11.04.013; 17.02.05.009; 24.06.02.010--
Pruritus23.03.12.001--
Purpura01.01.04.003; 23.06.01.004; 24.07.06.005--
Rash23.03.13.001---
Rash maculo-papular23.03.13.004--
Seizure17.12.03.001--
Stomatitis07.05.06.005--
Swelling face08.01.03.100; 10.01.05.018; 23.04.01.018---
Systemic lupus erythematosus10.04.03.004; 15.06.02.003; 23.03.02.006---
Tachycardia02.03.02.007---
Therapeutic response decreased08.06.01.016---
Tinnitus04.04.01.002; 17.04.07.004--
Urticaria10.01.06.001; 23.04.02.001--
Ventricular extrasystoles02.03.04.007---
Vomiting07.01.07.003--
Peripheral swelling02.05.04.015; 08.01.03.053---
Dysstasia08.01.03.089; 15.03.05.011; 17.02.02.012---
Musculoskeletal stiffness15.03.05.027---
Abnormal behaviour19.01.01.001---
Decreased appetite08.01.09.028; 14.03.01.005--
Psychotic disorder19.03.01.002--
Treatment failure08.06.01.0170.075251%-
Mouth swelling07.05.04.007; 10.01.05.020; 23.04.01.020---
Drug effect less than expected08.06.01.036---
Pharyngeal swelling22.04.05.028---
Symptom recurrence08.01.03.101---
Therapeutic product effect decreased08.06.01.050---
Brain fog16.32.03.050; 17.02.05.077; 19.21.02.017---
The 3th Page    First    Pre   3    Total 3 Pages